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Background. Few studies consider the incidence of individual AIDS-deﬁning illnesses (ADIs) at higher CD4
counts, relevant on a population level for monitoring and resource allocation.
Methods. Individuals from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE)
aged ≥14 years with ≥1 CD4 count of ≥200 µL between 1998 and 2010 were included. Incidence rates (per 1000 person-
years of follow-up [PYFU]) were calculated for each ADI within different CD4 strata; Poisson regression, using general-
ized estimating equations and robust standard errors, was used to model rates of ADIs with current CD4 ≥500/µL.
Results. A total of 12 135 ADIs occurred at a CD4 count of ≥200 cells/µL among 207 539 persons with
1 154 803 PYFU. Incidence rates declined from 20.5 per 1000 PYFU (95% conﬁdence interval [CI], 20.0–21.1 per
1000 PYFU) with current CD4 200–349 cells/µL to 4.1 per 1000 PYFU (95% CI, 3.6–4.6 per 1000 PYFU) with
current CD4≥ 1000 cells/µL. Persons with a current CD4 of 500–749 cells/µL had a signiﬁcantly higher rate of
ADIs (adjusted incidence rate ratio [aIRR], 1.20; 95% CI, 1.10–1.32), whereas those with a current CD4 of ≥1000
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cells/µL had a similar rate (aIRR, 0.92; 95% CI, .79–1.07), compared to a current CD4 of 750–999 cells/µL. Results were consistent
in persons with high or low viral load. Findings were stronger for malignant ADIs (aIRR, 1.52; 95% CI, 1.25–1.86) than for nonma-
lignant ADIs (aIRR, 1.12; 95% CI, 1.01–1.25), comparing persons with a current CD4 of 500–749 cells/µL to 750–999 cells/µL.
Discussion. The incidence of ADIs was higher in individuals with a current CD4 count of 500–749 cells/µL compared to those
with a CD4 count of 750–999 cells/µL, but did not decrease further at higher CD4 counts. Results were similar in patients virologi-
cally suppressed on combination antiretroviral therapy, suggesting that immune reconstitution is not complete until the CD4
increases to >750 cells/µL.
Keywords. CD4; virologic suppression; cART; AIDS deﬁning illnesses; immune reconstitution.
The decline in AIDS-deﬁning illnesses (ADIs) and deaths fol-
lowing the introduction of combination antiretroviral therapy
(cART) in 1996–1997 has been well documented [1–3]. Studies
have also described the decline in individual ADIs, such as
non-Hodgkin lymphoma, Pneumocystis jirovecii pneumonia,
Mycobacterium avium complex, Kaposi sarcoma, tuberculosis,
and cytomegalovirus infections [1, 4–7]. Prior to the introduc-
tion of cART, and in antiretroviral-naive patients, the incidence
of ADIs according to current CD4 count has been described [8, 9]
There is preliminary evidence that the risk of ADIs continues
to decrease as CD4 count increases, even at CD4 counts >500
cells/µL [9, 10], but, to our knowledge, there are few studies that
have speciﬁcally considered the incidence of individual ADIs at
higher CD4 counts [10, 11]. Previous work from the Collabora-
tion of Observational HIV Epidemiological Research Europe
(COHERE) has shown that the risk of a new ADI or death con-
tinued to decrease in patients with virological suppression where
the current CD4 count was >500 cells/µL, but the study did not
report the incidence of individual ADIs or investigate whether
there was an additional decrease at higher CD4 counts [12].
Approximately 80% of persons on cART are virologically sup-
pressed [13], but it is also relevant to determine the incidence
of ADIs overall and for speciﬁc diagnoses on a population level,
both for monitoring and for resource allocation. Knowledge of
the risk of a speciﬁc ADI at a given CD4 lymphocyte count and
the identiﬁcation of a possible threshold of immunodeﬁciency
have important implications for patient management, as well as
providing an important reference for the incidence of a wide
range of ADIs at higher CD4 counts.
The aims of this study were to describe the incidence of spe-
ciﬁc ADIs at CD4 counts of ≥200 cells/µL, according to the
latest CD4 count across a wide range of CD4 counts using data
from COHERE, a European collaboration of HIV cohort studies.
Our second objective was to determine the factors associated
with developing a new ADI at a CD4 count of ≥500 cells/µL.
METHODS
Patients
COHERE is a collaboration of 33 cohorts from across Europe.
COHERE was established in 2005 and merges data from
already established cohorts to conduct epidemiological research
on the prognosis of HIV-positive persons where the individual
contributing cohorts are not adequately powered. Local ethical
committee and/or other regulatory approval were obtained as
applicable according to local and/or national regulations in all
cohorts unless no such requirement applied to observational
studies according to national regulations. Each cohort submits
information using the standardized HIV Collaboration Data
Exchange Protocol (HICDEP; [14]) to coordinating centers at
the Copenhagen HIV Programme (CHIP), Copenhagen,
Denmark, or the Institut de Santé Publique d’Épidémiologie et
de Développement (ISPED), Bordeaux, France. Data collected
and analyzed herein were part of the 2011 merger, and included
data from the period 1998–2010. Data collected include infor-
mation on patient demographics, use of cART, CD4 cell
counts, ADIs, and deaths. ADIs were diagnosed using the 1993
classiﬁcation from the Centers for Disease Control and Preven-
tion [15]. COHERE is part of EuroCOORD, a network of excel-
lence established in 2010 (http://www.eurocoord.net/). Further
details about COHERE can be found at www.cphiv.dk and
http://etudes.isped.u-bordeaux2.fr/cohere/. All individuals in
COHERE aged ≥14 years with at least 1 CD4 count of ≥200
cells/ µL measured after 1 January 1998 with some prospective
follow-up were included in the analyses, regardless of their
current antiretroviral treatment or treatment history.
Statistical Methods
Baseline was deﬁned as the ﬁrst recorded CD4 count ≥200
cells/µL measured after 1 January 1998 (corresponding to the
widespread availability of cART); person-years of follow-up
(PYFU) were allocated to CD4 count strata (200–349, 350–499,
500–749, 750–999, and ≥1000 cells/µL) and the individual
ADIs allocated to the stratum they occurred in. Follow-up was
censored when the CD4 count fell below 200 cells/µL (and was
subsequently reentered into the analysis if the CD4 count rose
to ≥200 cells/µL) or at last CD4 count. Incidence rates were cal-
culated for each individual ADI occurring in >50 individuals,
and other diagnoses were combined to create an “other” cate-
gory. Recurrences of the same ADI were excluded but persons
could contribute >1 event to the analysis and moved through
CD4 count categories according to their current CD4 count.
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Poisson regression, using generalized estimating equations
and robust standard errors, were used to model rates of a new
ADI in persons with a current CD4 ≥500 cells/µL. Baseline for
this analysis was the ﬁrst CD4 count ≥500 cells/µL measured
after January 1998. Standard adjustments for other factors in-
cluded age, sex, HIV transmission group, ethnic origin, HIV
RNA load, duration of immune suppression (proportion of
follow-up time with CD4 count ≤200 cells/µL, including prior
to baseline for this analysis) or of controlled viremia (viral load
[VL] <400 copies/mL including time prior to baseline), and
starting cART. Within each CD4 count stratum, the current
CD4 count was included as a continuous variable to see if there
was a trend of an increasing rate of new ADIs at lower CD4
counts within CD4 stratum.
We performed a number of sensitivity analyses to investigate
if our results were robust in different populations. We excluded
the ﬁrst 6 months of follow-up to see if patients presenting with
ADIs were biasing our ﬁndings, and also limited analyses to
those with a deﬁnitive diagnosis, deﬁned by cohorts according to
the 1993 guidelines [15] and follow-up where the current CD4
count had been measured within the previous 6 months. We
also repeated the analysis in antiretroviral-naive persons by
right-censoring at starting cART, in those with VL <400 copies/
mL or >400 copies/mL, and in follow-up limited to the ﬁrst
6 months after initiation of cART. We also considered new
malignant ADIs (cervical cancer, Kaposi sarcoma, non-Hodgkin
lymphoma) and nonmalignant disease (all other ADIs) sepa-
rately, as well as pulmonary and extrapulmonary tuberculosis.
A subset of individuals had information available on CD8 count
and CD4 and CD8 percentages; additional models investigated
whether adjusting for these immunological markers, or ratios of
these, further explained our ﬁndings.
All analyses were performed using SAS software version 9.2
(SAS Institute Inc, Cary, North Carolina).
RESULTS
Of 250 553 individuals included in participating cohorts in
COHERE, 24 481 were excluded because they had no CD4
counts recorded of ≥200 cells/µL; a further 218 were excluded
because sex or information on date of birth was missing; 1930
were excluded because they were aged <14 years; and 16 385
were excluded because they had no prospective follow-up,
leaving 207 539 persons included in the analysis. Characteris-
tics at baseline are shown in Table 1; 149 730 persons were in-
cluded in the analysis focused on those with CD4 counts ≥500
cells/µL. The most common HIV transmission group was men
who have sex with men (MSM). The median CD4 at baseline
was 378 cells/µL (interquartile range [IQR], 264–548 cells/µL),
and 39 968 (19.3%) had a prior AIDS diagnosis.
A total of 12 135 of the ADIs observed occurred at a CD4
count of ≥200 cells/µL. The most common ADI was esophageal
candidiasis (n = 1629 [13.4%]), followed by Kaposi sarcoma
(n = 1323 [10.9%]) and pulmonary tuberculosis (n = 1263
[10.4%]). The median CD4 count at diagnosis ranged from 314
cells/µL (IQR, 252–450 cells/µL) in persons diagnosed with dis-
seminated Mycobacterium avium complex to 416 cells/µL
(IQR, 310–574 cells/µL) in persons diagnosed with recurrent
herpes infections. Incidence rates of new ADIs declined from
20.5 per 1000 PYFU (95% conﬁdence interval [CI], 20.0–21.1
per 1000 PYFU) in those with a current CD4 count of 200–349
cells/µL to 4.1 per 1000 PYFU (95% CI, 3.6–4.6 per 1000
PYFU) where current CD4 count was ≥1000 cells/µL. The
number of events, PYFU, and event rates within each CD4 count
stratum are shown for each ADI in Table 2, ordered from the
highest overall incidence to the lowest. Four ADIs—esophageal
candidiasis (1.4 [95% CI, 1.3–1.5]), Kaposi sarcoma (1.2 [95%
CI, 1.1–1.2]), pulmonary tuberculosis (1.1 [95% CI, 1.0–1.2]),
and extrapulmonary tuberculosis (1.1 [95% CI, 1.0–1.1])—had
overall incidence rates >1 per 1000 PYFU.
Factors associated with the development of a new ADI at a
current CD4 count of ≥500 cells/µL are shown in Table 3. Male
and female intravenous drug users had an increased rate of de-
veloping a new ADI, whereas male and female heterosexuals had
a lower rate. Persons with a current VL >10 000 copies/mL had a
higher rate, as did older individuals and those with a higher pro-
portion of follow-up time with a CD4 count <200 cells/µL. A
higher proportion of follow-up time with VL <400 copies/mL
was associated with a lower rate of new ADIs. Compared to
persons with a CD4 count of 750–999 cells/µL, those with a
current CD4 count of 500–749 cells/µL had a signiﬁcantly
higher rate of new ADIs (adjusted incidence rate ratio [aIRR],
1.20 [95% CI, 1.10–1.32], P < .0001), whereas those with a CD4
count of ≥1000 cells/µL had a similar rate (aIRR, 0.92 [95% CI,
.79–1.07], P = .26). Among persons with a current CD4 of 500–
749 cells/µL, a 50-cells/µL-lower CD4 count was associated with
a 6% increased rate of a new ADI (aIRR, 1.06 [95% CI, 1.02–
1.10], P < .0001), whereas in those with a CD4 count of 750–999
cells/µL, there was no evidence that a lower CD4 count within
this stratum was associated with an increased rate (aIRR, 1.01
[95% CI, .96–1.07], P = .72), or in those with a current CD4 of
≥1000 cells/µL (aIRR, 1.00 [95% CI, .98–1.03], P = .86).
We performed several sensitivity analyses; those considering
viral suppression or antiretroviral treatment are shown in
Figure 1. Results were consistent in antiretroviral-naive pa-
tients. There was no evidence that the relationship between
current CD4 and ADIs differed according to level of viral sup-
pression (P = .49, test for interaction). Compared to patients
with a current CD4 count of 750–999 cells/µL, those with a
CD4 count of 500–749 cells/µL had signiﬁcantly higher rates of
newADIs after adjustment in those with a low (<400 copies/mL)
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or high viral load (>400 copies/mL; Figure 1). During the
ﬁrst 6 months of cART, slightly different results were found
(Figure 1). After adjustment, compared to patients with a
current CD4 of 750–999 cells/µL, there was no increased rate of
a new ADI in those with either lower (500–749 cells/µL) or
higher current CD4 counts (>1000 cells/µL). Additional sensi-
tivity analyses are shown in Table 4. We removed the ﬁrst 6
months of follow-up for each individual due to concerns that a
signiﬁcant number of new ADIs might be diagnosed at, or soon
after, initial presentation, and found a 19% increased incidence
of a new ADI in those with a current CD4 count of 500–749
cells/µL compared to those with a current CD4 count of 750–
999 cells/µL (aIRR, 1.19 [95% CI, 1.08–1.32]). In an analysis
limited to those with only deﬁnitive diagnoses, there was a 22%
increased rate in those with a current CD4 count of 500–749
cells/µL (aIRR, 1.22 [95% CI, 1.05–1.41]). This increased rate
was somewhat higher for malignant ADIs (aIRR, 1.52 [95% CI,
1.25–1.86]) than for nonmalignant ADIs (aIRR, 1.12 [95% CI,
1.01–1.25]). Adjusting additionally for CD8, missing for ap-
proximately 20% of persons, did not alter our ﬁndings
(Table 4), but CD8 was a predictor of a new ADI; a CD8 count
>1000 cells/µL was associated with a higher rate of new ADIs
(aIRR, 1.16 [95% CI, 1.06–1.27], P = .0009).
DISCUSSION
This analysis included >200 000 HIV-infected individuals with
1 154 803 PYFU while at a current CD4 count of ≥200 cells/µL,
Table 1. Characteristics of Included Persons at Baseline; Collaboration of Observational HIV Epidemiological Research Europe
(COHERE), 1998–2010a
CD4 Count ≥200 Cells/µL CD4 Count ≥500 Cells/µL
Characteristic No. % No. %
All 207 539 100 149 730 100
HIV transmission group
MSM 83 831 40.4 64 929 43.4
Male IDU 21 973 10.6 14 247 9.5
Female IDU 8526 4.1 6066 4.1
Male heterosexual 31 913 15.4 20 763 13.9
Female heterosexual 41 682 20.1 30 546 20.4
Male other 13 300 6.4 8823 5.9
Female other 6314 3.0 4356 2.9
Country of origin
Developed country 86 445 41.7 65 037 43.4
Africa 20 425 9.8 13 018 8.7
Other 9498 4.6 6445 4.3
Unknown 91 171 43.9 65 230 43.6
Ethnic origin
White 68 127 32.8 51 939 34.7
Other 18 250 8.8 12 036 8.0
Unknown 121 162 58.4 85 755 57.3
Prior AIDS at baseline 39 968 19.3 26 931 18.0
VL <400 copies/mLb at baseline 66 370 33.1 76 989 52.9
On cART at baseline 92 103 44.4 86 198 57.5
ART naive at baseline 94 339 45.5 50 055 33.4
Measurements at Baseline Median IQR Median IQR
CD4 378 265–548 580 530–680
VLb 3.30 2.55–4.44 2.60 1.70–3.74
Baseline date (month/year) 12/2001 7/1998–11/2005 12/2002 7/1999–7/2006
Age 37 31–43 37 32–44
Abbreviations: ART, antiretroviral therapy; cART, combination ART; HIV, human immunodeficiency virus; IDU, intravenous drug user; IQR, interquartile range;
MSM, men who have sex with men; VL, viral load.
a Baseline defined as first CD4 ≥200 cells/µL (or ≥500 cells/µL) after 1 January 1998.
b Viral load data available for 200 827 (96.7%) of those with baseline CD4 count ≥200 cells/ul and 145 529 (97.2%) of those with baseline CD4 count ≥500 cells/uL
at baseline, respectively.
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including almost 150 000 persons and >550 000 PYFU with a
current CD4 count of ≥500 cells/µL, and described the inci-
dence of the 18 most commonly occurring ADIs in European
HIV Cohort studies, across a range of current CD4 stratum, up
to and including CD4 counts >1000/µL. Compared to patients
with a current CD4 count of 750–999 cells/µL, those with a
CD4 count of 500–749 cells/µL had a signiﬁcantly higher rate
of new ADIs, whereas those with current CD4 counts of >1000
cells/µL had a similar incidence. Within CD4 count strata
750–999 cells/µL and ≥1000 cells µL, there was no evidence of
a decreasing incidence of new ADIs within the strata. Highly
consistent results were found across a wide range of sensitivity
analyses.
The overall rate of new ADIs was low at current CD4 counts
≥500 cells/µL, <6 per 1000 PYFU, compared to a rate of >1000
per 1000 PYFU at current CD4 counts <50 cells/µL [9]. We
found an increased rate of new ADIs at a current CD4 count
of 500–749 cells/µL compared to 750–999 cells/µL or higher
but no evidence of any association between CD4 count and in-
cidence of new ADIs within the 750–999 cells/µL or ≥1000
cells/µL category, with quite narrow conﬁdence intervals, sug-
gesting that HIV-infected patients with a CD4 count ≥750
cells/µL have no further reduction in risk of new ADIs with
higher CD4 counts. We adjusted for other markers of immuno-
logical function, such as CD8, CD4 percentage, and CD8 per-
centage, in the subset of individuals with data, with consistent
results (data not shown). There are a number of studies that
have shown that having a current CD4 count ≥500 cells/µL is
beneﬁcial in terms of a combined endpoint of a new ADI and
death [9, 10, 12, 16], although these studies have been more
limited by power and have not split CD4 count stratum ≥500
cells/µL as in this current analysis.
Our results were consistent across a range of sensitivity anal-
yses, and were similar between antiretroviral-naive persons and
those who were or were not virologically suppressed, although
we were unable to say whether the ADIs experienced were
Table 2. Crude Incidence Rates (Per 1000 Person-years of Follow-up) of AIDS-Deﬁning Illnesses in CD4-Speciﬁc Strata
Stratum (Cells/µL)
ADI All 200–349 350–499 500–749 750–999 ≥1000
PYFU 1 154 803 274 441 324 134 354 069 138 039 64 120
Events 12 135 5632 3319 2271 648 265
Rate (95% CI) 10.5 (10.3–10.7) 20.5 (20.0–21.1) 10.2 (9.9–10.6) 6.4 (6.2–6.7) 4.7 (4.3–5.1) 4.1 (3.6–4.6)
AIDS defining illness
Esophageal candidiasis 1629/1.4/1.3–1.5 823/3.0/2.8–3.2 418/1.3/1.2–1.4 263/0.7/.7–.8 96/0.7/.6–.8 29/0.5/.3–.6
Kaposi’s sarcoma 1323/1.2/1.1–1.2 560/2.0/1.9–2.2 423/1.3/1.2–1.4 261/0.7/.7–.8 57/0.4/.3–.5 22/0.3/.2–.5
Pulmonary tuberculosis 1263/1.1/1.0–1.1 576/2.1/1.9–2.3 351/1.1/1.0–1.2 230/0.7/.6–.7 68/0.5/.4–.6 38/0.6/.4–.8
Non-Hodgkins lymphoma 1236/1.1/1.0–1.1 574/2.1/1.9–2.3 345/1.1/1.0–1.2 235/0.7/.6–.8 51/0.4/.3–.5 31/0.5/.3–.7
Extrapulmonary tuberculosis 997/0.9/.8–.9 491/1.8/1.6–2.0 282/0.9/.8–1.0 158/0.5/.4–.5 48/0.4/.3–.5 18/0.3/.2–.4
Bacterial pneumonia 898/0.8/.7–.8 384/1.4/1.3–1.5 264/0.8/.7–.9 174/0.5/.4–.6 58/0.4/.3–.5 18/0.3/.2–.4
Pneumocystis jirovecii pneumonia 840/0.7/.7–.8 507/1.9/1.7–2.0 196/0.6/.5–.7 112/0.3/.3–.4 18/0.1/.1–.2 7/0.1/.0–.2
Recurrent herpes simplex 778/0.7/.6–.7 274/1.0/.9–1.1 222/0.7/.6–.8 212/0.6/.5–.7 58/0.4/.3–.5 12/0.2/.1–.3
HIV dementia 750/0.7/.6–.7 314/1.1/1.0–1.3 196/0.6/.5–.7 166/0.5/.4–.5 56/0.4/.3–.5 18/0.3/.2–.4
Cervical cancera 190/0.6/.5–.7 71/0.9/.7–1.2 53/0.6/.4–.8 44/0.5/.3–.6 14/0.4/.2–.6 8/0.5/.2–.9
Other ADIs occurring in
<50 persons
495/0.4/.4–.5 196/0.7/.6–.8 135/0.4/.4–.5 115/0.3/.3–.4 35/0.3/.2–.3 14/0.2/.1–.4
HIV wasting syndrome 374/0.3/.3–.4 183/0.7/.6–.8 102/0.3/.3–.4 62/0.2/.1–.2 18/0.1/.1–.2 9/0.1/.1–.3
Progressive multifocal
leukoencephalopathy
307/0.3/.2–.3 167/0.6/.5–.7 78/0.2/.2–.3 50/0.1/.1–.2 8/0.1/.0–.1 4/0.1/.0–.2
Toxoplasmosis of brain 299/0.3/.2–.3 169/0.6/.5–.7 74/0.2/.2–.3 44/0.1/.1–.2 9/0.1/.0–.1 3/0.1/.0–.1
Cytomegalovirus (nonretinitis) 273/0.2/.2–.3 113/0.4/.3–.5 53/0.2/.1–.2 56/0.2/.1–.2 30/0.2/.1–.3 21/0.3/.2–.5
Cryptosporidiosis 174/0.2/.1–.2 66/0.2/.2–.3 54/0.2/.1–.2 37/0.1/.1–.1 8/0.1/.0–.1 9/0.1/.1–.3
Mycobacterium avium complex 127/0.1/.1–.1 78/0.3/.2–.4 24/0.1/.0–.1 15/0.0/.0–.1 8/0.1/.0–.1 2/0.0/.0–.1
Cytomegalovirus retinitis 95/0.1/.1–.1 45/0.2/.1–.2 27/0.1/.1–.1 16/0.1/.0–.1 6/0.0/.0–.1 1/0.0/.0–.1
Cryptococcosis 87/0.1/.1–.1 41/0.2/.1–.2 22/0.1/.0–.1 21/0.1/.0–.1 2/0.0/.0–.1 1/0.0/.0–.1
Data are presented as events/rate/95% CI for the rate.
Abbreviations: ADI, AIDS-defining illness; CI, confidence interval; HIV, human immunodeficiency virus; PYFU, person-years of follow-up.
a PYFU totaled 313 010 in females; 75 173, 88 209, 94 734, 37 084, and 17 811 in the CD4 count strata 200–349, 350–499, 500–749, 750–999, and ≥1000 cells/µL,
respectively.
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similar between those on and off cART or with and without vi-
rologic suppression. The relationship between current CD4 and
ADIs differed slightly during the ﬁrst 6 months of cART, with
no increased rate seen in those with a current CD4 count of
500–749 cells/µL compared to 750–999 cells/µL. The reasons
for this are unclear, but could reﬂect the increased rate of ADIs
in relation to high viremia irrespective of CD4 count during the
initial period after starting cART, compared to patients who
have been on cART for longer [6].
Our ﬁndings were stronger for malignant compared to non-
malignant ADIs. The strength of the association was similar
for Kaposi sarcoma and non-Hodgkin lymphoma (data not
Table 3. Factors Associated With a New AIDS-Deﬁning Illness With CD4 Count ≥500 Cells/µL
Univariate Analysis Multivariate Analysis
Factor IRR 95% CI P Value IRR 95% CI P Value
Current CD4, cells/µL
<750 1.33 1.22–1.46 <.0001 1.20 1.10–1.32 <.0001
750–999 1.00 . . . . . . 1.00 . . . . . .
≥1000 0.85 .74–.98 .029 0.92 .79–1.07 .26
HIV transmission group
MSM 1.00 . . . . . . 1.00 . . . . . .
Male IDU 1.13 .99–1.28 .066 1.24 1.09–1.40 .0009
Female IDU 1.50 1.28–1.77 <.0001 1.61 1.37–1.89 <.0001
Male heterosexual 0.86 .76–.97 .015 0.88 .78–.99 .037
Female heterosexual 0.86 .77–.95 .0043 0.88 .79–.97 .019
Male other 0.87 .72–1.04 .13 0.97 .82–1.14 .71
Female other 1.14 .90–1.43 .28 1.19 .95–1.48 .13
Country of origin
Developed 1.00 . . . . . . 1.00 . . . . . .
Africa 1.02 .88–1.19 .76 1.26 1.07–1.47 .0047
Other 0.97 .79–1.19 .76 1.13 .92–1.39 .24
Unknown 1.03 .95–1.12 .49 1.10 1.01–1.19 .026
Ethnic origin
White 1.00 . . . . . . 1.00 . . . . . .
Other 1.02 .88–1.15 .83 1.08 .92–1.26 .37
Unknown 0.85 .78–.92 <.0001 0.85 .78–.92 <.0001
Current VL, copies/mL
<400 1.00 . . . . . . 1.00 . . . . . .
400–10 000 1.28 1.16–1.42 <.0001 0.94 .82–1.07 .34
>10 000 2.60 2.36–2.85 <.0001 1.68 1.46–1.92 <.0001
Baseline AIDS
Yes vs no 1.32 1.20–1.45 <.0001 1.57 1.42–1.74 <.0001
Baseline
Per year later 1.04 1.03–1.06 <.0001 1.04 1.03–1.05 <.0001
Baseline cART
Yes vs no 0.88 .82–.95 .006 1.24 1.13–1.36 <.0001
Age
Per 10 y older 1.03 .99–1.08 .13 1.14 1.09–1.18 <.0001
Follow-up CD4≤ 200a
Per 10% longer 1.22 1.14–1.31 <.0001 1.17 1.09–1.25 <.0001
Follow-up VL < 400a
Per 10% longer 0.91 .90–0.92 <.0001 0.92 .90–.93 <.0001
Abbreviations: cART, combination antiretroviral therapy; CI, confidence interval; HIV, human immunodeficiency virus; IDU, intravenous drug user; IRR, incidence
rate ratio; MSM, men who have sex with men; VL, viral load.
a Included as time-updated variable and includes follow-up time prior to baseline.
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shown) while the model for cervical cancer did not converge
due to insufﬁcient numbers. Kaposi sarcoma is diagnosed
across a wide range of CD4 counts independent of CD4 nadir [17].
Most persons in this study had started cART at low CD4
count levels [18], and the onset of non-Hodgkin lymphoma
soon after cART initiation might be indicative of immune re-
constitution syndrome [19] or subclinical disease. COHERE is
an observational study, and confounding by indication is likely
to play a signiﬁcant role. Our ﬁndings should not therefore be
extrapolated to the “when to start cART” question. In time, the
randomized clinical trial START (Strategic Timing of Initiation
of Antiretroviral Therapy), with both AIDS and non-AIDS
clinical endpoints, will provide unbiased estimates of whether
cART is of net clinical beneﬁt to persons commencing therapy
at higher CD4 counts. The clinical beneﬁts of cART at higher
CD4 counts, where the reduction in risk is statistically but not
necessarily clinically signiﬁcant, need to be balanced against
the long-term potential costs and risks of antiretroviral therapy,
such as resistance development and adverse events including
cardiovascular and renal disease, and malignancies that may
add to other comorbidities associated with aging, immune acti-
vation, and HIV-related inﬂammation [20–22].
Other predictors of a new ADI included HIV transmission
group and HIV load, as previously reported [23–25]. Both pro-
portion of follow-up time with advanced immunodeﬁciency
(CD4 count ≤200 cells/µL) and with controlled viremia (<400
copies/mL) were independent predictors of a new ADI. Viremia
copy-years, a different way of measuring exposure to replicating
virus, has been shown to predict mortality independent of
current CD4 counts among those on cART [26]. This supports
ﬁndings from the SMART trial, which also showed that the
proportion of follow-up time with detectable viremia was, as
expected, higher in persons who interrupted vs continued
cART, and that the group that interrupted cART had an in-
creased risk of both ADI as well as various types of organ
disease [27].One explanation is that cumulative exposure to un-
controlled HIV replication is a surrogate for cumulative immune
system activation, inﬂammation, and depletion of lymphoid
organs from central memory and naive CD4+ T cells exhausting
the immune system [26, 28, 29]. Duration of immune deﬁciency
as a marker of disease progression has been investigated in
previous studies with varying degrees of immunodeﬁciency,
endpoints, and results [30–32]. It is likely that circulating
CD4 cells are a good but not a perfect marker of the immune
capacity in HIV infection, In addition, duration of immunode-
ﬁciency likely captures extra data not measured through the
CD4 count due to its variability [33] or differences in frequency
of measurement between persons.
This study has a number of limitations. We were not able to
adjust for hepatitis B or C status, or prior use of disease-speciﬁc
prophylaxis, as the data were quite limited. The incidence of
new ADIs at higher CD4 counts was extremely low, and our
results provide some evidence that there is a small increased
risk of a new ADI at CD4 counts of 500–750 cells/µL, but not
Figure 1. Relationship between current CD4 and AIDS-deﬁning illness with a CD4 count ≥500 cells/µL: relationship with current viral load and antiretro-
viral treatment. *Adjusted for human immunodeﬁciency virus transmission category, region of origin, region of presentation, age, baseline date, on combi-
nation antiretroviral therapy at baseline, AIDS diagnosis at baseline, CD4 nadir, proportion of follow-up time with CD4 count ≤200 cells/µL, and proportion
of follow-up time with viral load <400 copies/mL. Overall model also adjusts for current viral load (< or ≥400 copies/mL). Abbreviations: aIRR, adjusted in-
cidence rate ratio; ARV, antiretroviral; cART, combination antiretroviral therapy; CI, conﬁdence interval; VL, viral load.
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above this level. Although COHERE includes many of the Eu-
ropean observational cohorts, some regions, such as Eastern
Europe, are not well represented [18] and the incidence of spe-
ciﬁc ADIs in these regions may well differ from that presented
here [34]. In addition, cohorts have a range of quality assurance
systems, and we did not use case veriﬁcation for any ADIs.
Even small differences in reporting of ADIs could change the
incidence rates in these rare events considerably. COHERE
does not have complete information on non-AIDS events, and
we were unable to assess the relationship between non-AIDS
events and high CD4 counts, which form a signiﬁcant propor-
tion of morbidity and mortality in HIV-positive persons [35].
Table 4. Relationship Between Current CD4 and AIDS-Deﬁning Illness With CD4 Count ≥500 Cells/µL—Sensitivity Analyses
Crude Data Multivariate Modela
CD4 Count Events PYFU Rateb 95% CI aIRR 95% CI P Value
Excluding first 6 mo of follow-up for each person
500–749 cells/µL 1962 334 388 5.9 5.6–6.1 1.19 1.08–1.32 .0004
750–999 cells/µL 583 131 730 4.4 4.1–4.8 1.00 . . . . . .
≥1000 cells/µL 234 62 016 3.8 3.3–4.3 0.92 .78–1.07 .27
Total 2779 528 133 5.3 5.1–5.5
Including definitive diagnoses only
500–749 cells/µL 857 354 069 2.4 2.3–2.6 1.22 1.05–1.41 .011
750–999 cells/µL 261 138 039 1.9 1.7–2.1 1.00 . . . . . .
≥1000 cells/µL 96 64 120 2.2 2.1–2.3 0.88 .71–1.09 .15
Total 1214 556 228
CD4 current for 6 mo only
500–749 cells/µL 2017 308 191 6.5 6.3–6.8 1.20 1.09–1.32 .0003
750–999 cells/µL 587 119 864 4.9 4.5–5.3 1.00 . . . . . .
≥1000 cells/µL 235 55 487 4.2 3.7–4.8 0.93 .80–1.10 .41
Total 2839 483 541 5.9 5.7–6.1
Malignant ADIs
500–749 cells/µL 555 354 069 1.7 1.5–1.8 1.52 1.25–1.86 <.0001
750–999 cells/µL 129 138 039 1.0 .8–1.2 1.00 . . . . . .
≥1000 cells/µL 61 64 120 1.1 .7–1.2 1.07 .78–1.47 .67
Total 745 556 228 1.4 1.3–1.5
Nonmalignant ADIs
500–749 cells/µL 1745 354 069 5.2 5.0–5.5 1.12 1.01–1.25 .026
750–999 cells/µL 542 138 039 4.1 3.8–4.5 1.00 . . . . . .
≥1000 cells/µL 206 64 120 3.3 2.9–3.8 0.88 .74–1.04 .13
Total 2493 556 228 4.7 4.5–4.9
Tuberculosis-related ADIs (pulmonary and extrapulmonary)
500–749 cells/µL 395 354 069 1.2 1.1–1.3 1.12 .90–1.39 .30
750–999 cells/µL 120 138 039 0.9 .8–1.1 1.00 . . . . . .
≥1000 cells/µL 56 64 120 0.9 .7–1.1 1.05 .75–1.47 .76
Total 571 556 228 1.1 1.0–1.2
With CD8 values availablec
500–749 cells/µL 1662 278 438 6.0 5.7–6.3 1.17 1.05–1.31 .0033
750–999 cells/µL 498 108 793 4.6 4.2–5.0 1.00 . . . . . .
≥1000 cells/µL 192 50 670 3.8 3.3–4.3 .88 .74–1.05 .16
Total 2352 437 901 5.4 5.2–5.6
Abbreviations: ADI, AIDS-defining illness; aIRR, adjusted incidence rate ratio; CI, confidence interval; PYFU, person-years of follow-up.
a Adjusted for HIV transmission category, region of origin, region of presentation, current viral load, age, baseline date, on combination antiretroviral therapy
at baseline, AIDS diagnosis at baseline, CD4 nadir, proportion of follow-up time with CD4 ≤200 cells/µL, and proportion of follow-up time with viral load
<400 copies/mL.
b Rate per 1000 PYFU.
c Adjusted additionally for CD8 count (≤1000 cells/µL and >1000 cells/µL).
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In conclusion, the incidence of speciﬁc ADIs varied widely
among persons with current CD4 counts 200–499 cells/µL and
was generally low among all persons at higher CD4 counts.
Despite this low rate of new ADIs at current CD4 counts ≥500
cells/µL, the rate was increased by 20% when compared to those
with a current CD4 of 750–999 cells/µL, whereas there were no
further signiﬁcant reductions in ADIs at higher CD4 counts.
Results were similar in those with viral suppression and stronger
for malignant than nonmalignant events, suggesting that immune-
mediated mechanisms other than those induced by HIV replica-
tion alone are responsible for this increased rate. Persons with
HIV infection are not fully immune reconstituted until the CD4
count increases to >750 cells/µL.
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